In a Series A funding round led by Ecolab, Leucine, a b2b startup providing software to pharmaceutical firms in India and the US, secured $7 mn.
Pravega Ventures, Axilor Ventures, Techstars, and angel investors were among the additional investors.
The startup intends to use the money to expand its tech infrastructure and enhance its AI capabilities. Additionally, the new funds will be used to broaden the company’s reach and boost its customer base.
Read also – Insurtech Startup BimaKavach Secures IRDAI License for Business Insurance
“Our models are trained on a wealth of pharma data, which allows the platform to create custom workflows enriched with GxP compliance measures, enabling us to deliver unparalleled value at breakneck speed,” Leucine cofounder and CEO Vivek Gera said.
In more than 300 pharmaceutical manufacturing facilities spread across 10 countries, including the US, India, Brazil, Mexico, UAE, and others, leucine is currently being used. Their clients have faith in us to assist them in getting secure medications into the hands of patients all over the world.
Read alsco – [Funding alert] Freyr Energy Raises $7 Mn Series B Funding From EDFI ElectriFI, Others
“Vivek and Mustaq have been relentless in their mission to make pharma manufacturing safer. This latest funding round will enable Leucine to bring the power of LLMs (large language models) and associated technologies to make significant advances in pharma manufacturing,” Rohit Jain, cofounder and partner at Pravega Ventures, said.
Built on proprietary LLM technology, Leucine 10X offers an army of AI co-pilots that perform highly specialized tasks such as digitizing paper-based SOPs, creating a digital twin of the shop floor, collaborating with Production Managers in creating dynamic production plans, thus ensuring on-time batch delivery.
Read also – Vivek Bhutyani Joins Pocket FM as VP – Content Marketing
About Leucine
An AI-powered platform called Leucine assists pharmaceutical companies in maintaining compliance and being audit-ready while ensuring that their medications get to patients more quickly.
